

Appendix Table F140. Comparative effectiveness of medical devices (individual RCTs)

Reference sample	Active	Control	Definition of outcome	Randomized active/control	Active events/rate	Control events/rate	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Williams, 2006 ⁶¹⁵ /0	Vaginal cone therapy	Primary behavioral intervention	Odds ratio of no symptoms (cure)	80/79			0.88 (0.28; 2.76)			
Williams, 2006 ⁶¹⁵ /0	Vaginal cone therapy	Primary behavioral intervention	Odds ratio of mild or no problem	80/79			0.88 (0.44; 1.77)			
Thyssen, 2001 ⁶⁰⁸ 124/0	Contrelle Continenace Tampon (CCT)	Conveen Continenace disposable Intravaginal device guard, (CCG)	Subjectively continent	62/62	30/48	22/35	1.36 (0.89; 2.08)	0.13 (-0.04; 0.30)		
Thyssen, 2001 ⁶⁰⁸ 188/0	Conveen Continenace disposable Intravaginal device guard, (CCG)	Contrelle Continenace Tampon (CCT)	Cured from stress urinary incontinence	94/94	34/36	45/48	0.76 (0.54; 1.06)	-0.12 (-0.26; 0.02)		
Nygaard, 1995 ⁵⁷⁹ 40/0	Hodge pessary with support	40-minute standardized aerobics sessions wearing a super tampon	Continent during exercise	20/20	7/36	12/58	0.58 (0.29; 1.17)	-0.25 (-0.55; 0.05)		
Andersen, 2002 ⁴⁸² 52/0	Durasphere	Contigen®	Dry	26/26	10/38	3/12	3.33 (1.03; 10.74)	0.27 (0.05; 0.49)	4 (2; 22)	269 (46; 493)
Robinson, 2003 ⁵⁹⁰ 24/0	Urethral device (NEAT) –sterile urethral insert with disposable applicator packaged with device.	Reliance Insert sterile balloon type device	Success as negative pad weight test	13/11	9/73	7/62	1.09 (0.61; 1.93)	0.06 (-0.32; 0.44)		

Appendix Table F140. Comparative effectiveness of medical devices (individual RCTs) (continued)

Reference sample	Active	Control	Definition of outcome	Randomized active/control	Active events/rate	Control events/rate	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Improvement in incontinence										
Thyssen, 2001 ⁶⁰⁸ 124/0	Contrelle Continence Tampon (CCT)	Conveen Continence disposable Intravaginal device guard (CCG)	Improvement in UI	62/62	22/35	25/40	0.88 (0.56; 1.38)	-0.05 (-0.22; 0.12)		
Thyssen, 2001 ⁶⁰⁸ 188/0	Conveen Continence disposable Intravaginal device guard (CCG)	Contrelle Continence Tampon (CCT)	Self reported Improvement in stress urinary incontinence	94/94	38/40	34/36	1.12 (0.78; 1.61)	0.04 (-0.10; 0.18)		
Andersen, 2002 ⁴⁸² 52/0	Durasphere	Contigen®	Improvement of 1 or more continence grades	26/26	20/77	13/50	1.54 (0.99; 2.38)	0.27 (0.02; 0.52)	4 (2; 56)	269 (18; 521)
Seo, 2004 ⁵⁹⁴ 120/0	Pelvic floor exercise (5 sec contraction and 10 sec relaxation, 3-5 times for >5 min/day) and functional Electrical Stimulation Biofeedback (35Hz-50Hz for 24 sec); 2 training sessions/week	Vaginal cone, 150-gram dumbbell- shaped made of fine ceramic material	Self reported improvement in urinary incontinence	60/60	55/92	53/88	1.04 (0.92; 1.17)	0.03 (-0.07; 0.14)		

Appendix Table F140. Comparative effectiveness of medical devices (individual RCTs) (continued)

Reference sample	Active	Control	Definition of outcome	Randomized active/control	Active events/rate	Control events/rate	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Robinson, 2003 ⁵⁹⁰ 24/0	Urethral device (NEAT) –sterile urethral insert with disposable applicator packaged with device.	Reliance Insert sterile balloon type device	Success as a 50% or greater reduction in urine loss	13/11	9/67	6/58	1.27 (0.66; 2.43)	0.15 (-0.24; 0.53)		